PAVmed Inc., a medical device company operating in the United States, has developed several innovative products for minimally invasive surgical procedures and the early detection of certain types of cancer. The company's lead products include CarpX, which is a patented and single-use disposable device used to treat carpal tunnel syndrome in a minimally invasive manner. Additionally, PAVmed Inc. has developed EsoCheck, which is an esophageal cell collection device used for the early detection of adenocarcinoma and Barrett's Esophagus (BE), and EsoGuard, a next-generation DNA sequencing assay that uses bisulfite conversion. The company's pipeline includes other promising products like EsoCure for dysplastic BE, PortIO, an implantable intraosseous vascular access device, NextFlo, and Veris cancer care platform. PAVmed Inc. was formerly known as PAXmed Inc. and changed its name in April 2015. The company was incorporated in 2014 and is headquartered in New York, New York.